About Donmienne Leung
Donmienne Leung is a director, abbvie ventures at Endlyz Therapeutics.
Experience
This experience comes from Donmienne Leung's profile and from SEC filings. For roles taken from filings, the years are when the filings name Donmienne Leung in the role, so the role may have started earlier or lasted longer.
TH
ThirtyFiveBio Current
Board Member
2025 – Present
CE
Cephagenix Current
Board Member
2025 – Present
ET
EvolveImmune Therapeutics Current
Board Member
2024 – Present
Endlyz Therapeutics, Inc. Current
Director, AbbVie Ventures
2023 – Present · Boston, MA
Develops potential medicines for people with Parkinson’s disease and other dementias.
AB
AbbVie Current
Director II, Head of Ventures Europe
2023 – Present
EP
Enthera Pharmaceuticals
Board Observer
2023 – 2025
DG
DISCO Pharmaceuticals GmbH
Board Observer
2023 – 2025
AB
Absolute Biotech
Head of Protein Engineering
2021 – 2023
EC
Eli Lilly and Company
Senior Research Advisor
2005 – 2021
TI
The Scripps Research Institute
Postdoctoral Scientist
2001 – 2005
UQ
University of Queensland
PHD Student
1997 – 2001
UM
University of Melbourne
Honors Student
1996 – 1997
WR
Walter and Eliza Hall Institute of Medical Research
Research Assistant
1994 – 1996
Key Colleagues at Startups
The people Donmienne Leung works with at each company, as listed on that company's latest Form D.
Endlyz Therapeutics, Inc. · Form D, May 7, 2026
JF
Justian Fox
Director
Laurence Barker
Partner, SV Health Investors and director
Timothy Edwards
Chairperson, Independent
Joanna Wolak
CEO and Co-founder, director